Skip to main content
    E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.96
    -0.04 (-0.80%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 4:19 PM ET

    Entrada Therapeutics Inc (TRDA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Entrada Therapeutics (TRDA) has a market cap of $199.28M and an enterprise value of $134.35M. It kept -4057.98% of revenue as net income over the last 12 months. Revenue fell 93.54% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 32.58% below the market cap, as cash exceeds debt.

    Market Cap$199.28M
    Enterprise Value$134.35M
    Latest price (Nov 17, 2026)$4.96

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.36% in the quarter ended Sep 30, 2026 and grew 2.12% a year over 2 years.

    Shares Outstanding42.37M
    Shares Change (YoY)+2.20%
    Shares Change (QoQ)+0.36%
    Share Count Growth (2Y CAGR)+2.12%

    Valuation Ratios

    Sales and book value multiples are 52.8x and 1.1x. Its year-end P/S ranged from 2.9x to 16.6x from 2023 to 2025.

    P/S Ratio52.8x
    Forward P/S49.2x
    P/B Ratio1.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 43.31% over 52 weeks and trades 9.82% below its 50-day average.

    Beta (1Y)1.55
    52-Week Change-43.31%
    1-Month Change+2.90%
    3-Month Change-36.25%
    6-Month Change-12.21%
    5-Year Change-81.06%
    Total Return (1Y)-43.31%
    Total Return (3Y CAGR)-32.62%
    Total Return (5Y CAGR)-31.90%
    Return vs SPY (1Y)-55.32%
    Max Drawdown (1Y)-72.74%
    Max Drawdown (3Y)-79.76%
    Sharpe Ratio (1Y)-0.53
    Correlation with SPY (1Y)0.19
    50-Day Average$5.50
    200-Day Average$8.39
    52-Week Range$4.11 to $16.45
    RSI (14 Days)48.2
    Average Volume (20 Days)510.06K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.85x current liabilities, and total debt is 0.24x shareholder equity.

    Current Ratio7.85x
    Quick Ratio7.85x
    Debt / Equity0.24x
    Interest Coverage-2.41x

    Returns and Efficiency

    Return on invested capital is -69.68% over the last 12 months, against a 5-year average of -51.58%.

    Return on Equity (ROE)-81.37%
    Return on Assets (ROA)-60.47%
    Return on Invested Capital (ROIC)-69.68%
    ROE (5Y Average)-19.21%
    ROA (5Y Average)-16.26%
    ROIC (5Y Average)-51.58%
    Asset Turnover0.01x

    Scores

    TRDA has an Altman Z-Score of -1.54, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.54
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $3.98M over the last 12 months.

    Revenue$3.98M
    Revenue Growth (YoY)-93.54%
    Gross Profit$3.98M
    Operating Income-$171.16M
    Pretax Income-$161.19M
    Net Income-$161.39M
    Reported EPS (TTM)-$3.84

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.31% of the $266.88M in total assets.

    Cash and Equivalents$112.24M
    Total Debt$47.31M
    Net Cash$64.92M
    Net Cash Per Share$1.53
    Working Capital$177.09M
    Shareholder Equity$198.32M
    Book Value Per Share$4.68
    Total Assets$266.88M
    Total Liabilities$68.56M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $423.00K of capital spending, operating cash flow left -$136.75M of free cash flow.

    Operating Cash Flow-$136.32M
    Capital Expenditures$423.00K
    Free Cash Flow-$136.75M
    FCF Per Share-$3.51
    Depreciation and Amortization$5.09M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4303.82%.

    Gross Margin100.00%
    Operating Margin-4303.82%
    Pretax Margin-4053.16%
    Net Margin-4057.98%
    FCF Margin-3438.47%

    Growth

    Book Value Per Share Growth (2Y CAGR)+0.94%
    Tangible Book Per Share Growth (2Y CAGR)+0.94%

    Revenue and profit by year

    Dividends and Yields

    TRDA does not pay a dividend. Its free cash flow yield is -65.06%.

    FCF Yield-65.06%
    Buyback Yield-0.07%
    Shareholder Yield-0.07%

    Peer Position

    Against 9 similar companies, TRDA has the highest P/S.

    P/S Ratio52.8x vs 7.0x median
    ROIC-69.68% vs -8.94% median
    Revenue Growth (Trailing 4 Quarters, YoY)-93.54% vs +0.18% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -10.52% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-10.52%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TRDA

    What is TRDA's market cap?

    Entrada Therapeutics has a market cap of $199.28M. Its enterprise value, which adds debt and subtracts cash, is $134.35M.

    How many shares of TRDA are outstanding?

    Entrada Therapeutics has 42.37M shares outstanding. The count is up 2.20% from a year earlier.

    Does TRDA pay a dividend?

    No. Entrada Therapeutics does not pay a dividend.

    How much debt does TRDA have?

    Entrada Therapeutics has $47.31M of total debt and $112.24M of cash and equivalents, a net cash position of $64.92M.